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Chronic renal failure is an important clinical problem
with significant socioeconomic impact worldwide.
Despite advances in renal replacement therapies and
organ transplantation, poor quality of life for dialysis
patients and long transplant waiting lists remain major
concerns for nephrologists treating this condition.
There is therefore a pressing need for novel therapies
to promote renal cellular repair and tissue remodeling.
Over the past decade, advances in the field of
regenerative medicine allowed development of cell
therapies suitable for kidney repair. Mesenchymal stem
cells (MSCs) are undifferentiated cells that possess
immunomodulatory and tissue trophic properties and
the ability to differentiate into multiple cell types.
Studies in animal models of chronic renal failure have
uncovered a unique potential of these cells for
improving function and regenerating the damaged
kidney. Nevertheless, several limitations pertaining to
inadequate engraftment, difficulty to monitor, and
untoward effects of MSCs remain to be addressed.
Adverse effects observed following intravascular
administration of MSCs include immune rejection,
adipogenic differentiation, malignant transformation,
and prothrombotic events. Nonetheless, most studies
indicate a remarkable capability of MSCs to achieve
kidney repair. This review summarizes the regenerative
potential of MSCs to provide functional recovery from
renal failure, focusing on their application and the
current challenges facing clinical translation.* Correspondence: Lerman.Lilach@Mayo.Edu
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Chronic kidney disease (CKD) is a prevalent condition
(8 to 16%) associated with all-cause and cardiovascular
mortality [1]. Importantly, CKD can progress towards
end-stage renal disease (ESRD), requiring renal replace-
ment therapy. ESRD currently accounts for 6.3% of the
Medicare spending in the United States, and is projected
to increase by 85% by 2015 [2]. Furthermore, ESRD has
a tremendous impact on quality of life and life expect-
ancy of affected individuals [3]. Therefore, it is impera-
tive to develop therapeutic interventions to prevent,
alleviate, or decelerate progression of renal failure.
Diabetes mellitus and hypertension represent major
causes of CKD and initiation of dialysis in the United
States [4]. In addition, glomerular diseases, malnutrition,
infectious diseases, and acute kidney injury can progress
to ESRD, contributing to the increased global burden of
death associated with this condition [5]. Current treat-
ment modalities often fail to target the major underlying
contributors for progression of renal disease [6]. Chronic
glomerular and tubulointerstitial fibrosis is a common
pathway to ESRD, often associated with apoptosis, oxida-
tive damage, and microvascular rarefaction. In fact, renal
dysfunction is postulated to better correlate with the de-
gree of tubulointerstitial than with glomerular damage [7].
Importantly, the kidney possesses intrinsic regenerative
capacity that allows the organ to recover after limited in-
sults [8]. Unfortunately, this regenerative potential is lim-
ited under chronic conditions and thus inefficient to
prevent progressive glomerulosclerosis and tubulointersti-
tial fibrosis [9]. Treatment strategies that boost cellular re-
generation might therefore offer good alternatives for
patients with CKD.
Mesenchymal stem cells (MSCs) can be isolated from a
variety of tissues, differentiate into multiple cell lineages,
and possess unique immunomodulatory properties that
ameliorate inflammation and immune responses, constitut-
ing a promising tool to facilitate renal repair. MSCs are de-
fined by the presence of plastic-adherent cells under
standard culture conditions, capacity to differentiate intontral Ltd. The licensee has exclusive rights to distribute this article, in any
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ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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sion of typical surface markers (CD29, CD44, CD73, CD90,
CD105, and CD166), and the lack of CD45, CD34, CD14
or CD11b, CD79α or CD19 and HLA-DR surface mole-
cules [10]. In recent years, experimental studies have un-
covered the potential of MSCs to improve renal function in
several models of CKD, and several clinical studies have in-
dicated their safety and efficacy in CKD. Nevertheless, a
number of hurdles need to be addressed before clinical
translation. This review summarizes the current state of
MSC transplantation for CKD, focusing on their mecha-
nisms of renal repair, complications, obstacles for clinical
translation, and potential approaches to overcome them.
Mesenchymal stem cells in experimental chronic
kidney disease
Over the past few years, MSCs have been successfully ap-
plied in experimental models of CKD such as diabetes,
hypertension, and chronic allograft nephropathy (Table 1).
For example, a single intravenous dose of MSCs resulted
in beta-pancreatic islet regeneration, prevented renal dam-
age in streptozotocin-induced type 1 diabetes in C57BL/6
mice [11], and decreased hyperglycemia and glycosuria
that persisted for 2 months after injection. Furthermore,
MSC-treated diabetic mice showed histologically normal
glomeruli, and albuminuria fell. Although the authors did
not assess cellular mechanisms associated with MSC
therapeutic effects, the long-lasting persistence of injected
MSCs may suggest a direct effect to elicit kidney
regeneration.
Similarly, Lee and colleagues tested the effectiveness of
intracardiac infusions of MSCs from human bone mar-
row in immunodeficient mice with type 2 diabetes pro-
duced with multiple low doses of streptozotocin [12].
MSCs lowered blood glucose levels and decreased
mesangial thickening and macrophage infiltration, sug-
gesting their potential for improving renal lesions in
subjects with diabetes mellitus. Interestingly, in kidneys
of MSC-treated diabetic mice, a few injected human
MSCs differentiated into glomerular endothelial cells.
Additionally, in rats with modified 5/6 nephrectomy, a
single venous injection of MSCs 1 day afterTable 1 Preclinical studies using mesenchymal stem cells for
Disease Source Dose Ro
Diabetic nephropathy Mice bone marrow 0.5 × 106 In
Diabetic nephropathy Human bone marrow 2 × 106 In
Partial nephrectomy Rat bone marrow 1 × 106 In
Chronic allograft nephropathy Rat bone marrow 0.5 × 106 In
Renal revascularization Allogeneic swine
adipose tissue
10 × 106 In
Renal artery stenosis Autologous swine
adipose tissue
10 × 106 Innephrectomy preserved renal function and attenuated
renal injury [13]. Despite unchanged blood urea nitrogen
and creatinine levels, MSC-treated animals showed at-
tenuated progression of proteinuria. The scarce en-
graftment of MSCs in the kidneys of rats with
chronic renal failure suggests that paracrine secretion
of mediators, such as cytokines or growth factors,
may have accounted for their beneficial effects. In-
deed, vascular endothelial growth factor (VEGF) levels
were substantially higher in MSC-treated animals
1 month after MSC injection.
Furthermore, a single dose of bone marrow-derived
MSCs 11 weeks after kidney transplantation in rats de-
creased interstitial fibrosis, tubular atrophy, T-cell and
macrophage infiltration, and the expression of inflamma-
tory cytokines [14]. Interestingly, a decrease over time in
the inflammatory and profibrotic cytokine levels in
MSC-treated animals was associated with an increase in
the anti-inflammatory cytokine IL-10, although none of
the injected MSCs were detected 7 days after delivery.
These observations imply that the beneficial effect of
these cells in this setting is primarily attributable to their
paracrine immunomodulatory properties rather than
long-term engraftment.
We have previously shown in swine atherosclerotic reno-
vascular disease that intrarenal delivery of MSCs isolated
from subcutaneous adipose tissue protected the stenotic
kidney despite sustained hypertension [15]. Notably, MSCs
also attenuated renal inflammation, endoplasmic-reticulum
stress, and apoptosis through mechanisms involving cell
contact. Furthermore, adjunctive MSCs improved renal
function and structure after renal revascularization and
reduced inflammation, oxidative stress, apoptosis, micro-
vascular remodeling, and fibrosis in the stenotic kidney
[16] (Figure 1). This strategy also restores oxygen-
dependent tubular function in the stenotic-kidney medulla,
extending their value to preserving medullary structure and
function in chronic ischemic conditions [17].
Potential challenges for clinical translation
While preclinical studies have established the safety and
efficacy of MSCs in different models of CKD, thesethe treatment of chronic kidney disease
ute Mechanism of action Side effects Reference
travenous Engraftment/direct effect None [11]
tracardiac Engraftment/direct effect None [12]
travenous Paracrine effect None [13]







Figure 1 Stenotic-kidney microvascular loss and fibrosis decreased in animals treated with mesenchymal stem cells. Top: representative
microcomputed tomography three-dimensional images of kidney segments, showing improved microvascular architecture in pigs with atherosclerotic
renal artery stenosis (ARAS) treated with percutaneous transluminal renal angioplasty (PTRA) and an adjunct intrarenal infusion of adipose
tissue-derived mesenchymal stem cells (MSC) 4 weeks earlier. Bottom: representative renal trichrome staining (×40, blue) showing decreased fibrosis in
ARAS + PTRA + MSC pigs.
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practice. Trials using MSCs for CKD patients may face
various challenges, including selecting the optimal route
of MSC delivery, scant homing and engraftment, im-
mune rejection, ensuring thriving, and tracking of
injected cells. Addressing these challenges may bolster
the success of MSC therapy in improving renal function
in CKD patients.
Route of delivery
The route of MSC delivery may influence the cells’ cap-
acity to home and engraft the damaged tissue, and
thereby their efficacy for renal repair. Commonly used
experimental methods to deliver MSCs include systemic
intravenous, intra-arterial, or intraparenchymal delivery.
When intravenously delivered in normal Sprague–Daw-
ley rats, the majority of MSCs are initially trapped in the
lungs [18], but in nonhuman primates the cells distrib-
ute broadly into the kidneys, skin, lung, thymus, and
liver with estimated levels of engraftment ranging from
0.1 to 2.7% [19]. In contrast, direct delivery of MSCs
into the renal artery of an ischemic kidney is associated
with retention rates of 10 to 15% [16,17], although the
normal swine kidney retains only around 4%, due to the
low tonic release of injury signals. However, injection of
human MSCs into the mouse abdominal aorta may lead
to occlusion in the distal vasculature due to their rela-
tively large cell size (16 to 53 μm), suggesting that this
approach should be used cautiously [20]. Injections of
MSCs into the renal parenchyma or their localsubcapsular implantation confer renoprotective effects
[21,22], but are difficult to implement in the human in-
jured kidney.
In experimental models of CKD, the optimal dose of
MSCs is often empirical, with doses ranging from 0.5 × 106
to 10 × 106 [11,16]. Despite variability in dose regimens
and route of delivery, the safety and beneficial effects of
MSCs were consistent among studies. Nevertheless, the
use of escalating doses is strongly recommended in clinical
trials, and chronic adverse events should be evaluated
prior to enrollment at the next dose level.
Homing
Circulating hematopoietic progenitor cells home to the
damaged kidney by responding to injury signals that cor-
respond to cognate surface receptors which they express
[23]. Accumulating evidence indicates that exogenously
infused MSCs respond to similar homing signals. In
mice, expression of CD44 and its major ligand hyalur-
onic acid mediates MSC migration to the injured kidney
[24], and hyaluronic acid also promotes MSC dose-
dependent migration in vitro. Moreover, renal homing of
intravenously injected MSCs was blocked by preincuba-
tion with the CD44 blocking antibody or by soluble hya-
luronic acid, suggesting that CD44 and hyaluronic acid
interactions recruit exogenous MSCs to the injured kid-
ney. In addition, Liu and colleagues found that, when
administered systemically, MSCs home to the ischemic
kidney, improving renal function, accelerating mitogenic
response, and reducing cell apoptosis, but these effects
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implicating the stromal derived factor-1–CXCR4/CXCR7
axis in kidney repair [25].
Collectively, these observations suggest that strategies
aimed to enhance MSC expression of homing signals may
improve their capacity to attenuate renal dysfunction.
Studies have shown that selective manipulation of MSCs
before transplantation (preconditioning) enhances their
ability to protect damaged tissues [26,27]. The rationale
underpinning this approach is that transplanted MSCs en-
counter a hostile microenvironment that mitigates their
reparative capabilities and survival. Indeed, precondition-
ing with the mitogenic and prosurvival factor insulin-like
growth factor (IGF)-1 before systemic infusion of bone
marrow-derived MSCs (2 × 105) upregulates the expres-
sion of CXCR4 and restores normal renal function in a
mice model of cisplatin-induced acute kidney injury [28].
Engraftment
Some studies suggest that MSCs have the capacity to en-
graft the damaged tissue, integrate into tubular cells, and
differentiate into mesangial cells [29-31]. In swine reno-
vascular disease, 4 weeks after intrarenal infusion, MSCs
(10 × 106) were detected in all regions of the kidney, but
mostly at the renal interstitium [16,17]. On the other
hand, intravenous infusion of bone marrow-derived MSCs
(2 × 105) in mice with cisplatin-induced acute renal failure
reduced the severity of renal injury, but none were de-
tected within the renal tubules and only few cells within
the renal interstitium at 1 to 4 days after infusion [32],
suggesting that MSC engraftment is not necessary to
achieve renoprotection. Likewise, despite significant im-
provement in renal function, within 3 days of intracarotid
infusion in a rat model of ischemia–reperfusion-induced
acute renal failure, none of the MSCs differentiated into
the tubular or endothelial cell phenotype, indicating that
their beneficial effects are primarily mediated via paracrine
actions rather than differentiation into target cells [33].
Methods to increase MSC engraftment may therefore
enhance their utility in regenerative cellular therapy. Tem-
porary obstruction of the renal artery following intrarenal
delivery [16,17] may prevent cell washout, and is associ-
ated with significant retention rates in the postischemic
kidney. Alternatively, in a rat model of acute kidney injury,
s-nitroso N-acetyl penicillamine preconditioning enhances
MSC engraftment, ultimately associated with a significant
improvement in renal function [34].
Despite the crucial role attributed to MSC engraftment
in potentiating the cells’ beneficial effect at the site of in-
jury, there is currently consensus that the chief mechan-
ism by which MSCs protect the damaged kidney is the
release of growth factors, proangiogenic factors, and
anti-inflammatory cytokines. Cultured MSCs release
large amounts of the proangiogenic factor VEGF, whichfacilitates glomerular and tubular recovery [16,35].
MSCs can also produce IGF-1, while administration of
IGF-1 gene-silenced MSCs limits their protective effect
on renal function and tubular structure in murine
cisplatin-induced kidney injury, indicating that MSCs
exert their beneficial effects by producing IGF-1 [36].
Importantly, these paracrine actions of MSCs seem to
mediate their immunomodulatory properties. In ische-
mia–reperfusion-induced acute kidney injury, infusion of
MSCs downregulates renal expression of proinflamma-
tory cytokines and adhesion molecules such as IL-1β,
tumor necrosis factor alpha, interferon gamma, mono-
cyte chemoattractant protein-1, and intercellular adhe-
sion molecule-1, but upregulates the expression of the
anti-inflammatory IL-10 [26,33]. Likewise, we have
shown in swine renovascular disease that intrarenal de-
livery of MSCs during renal revascularization decreased
renal expression of tumor necrosis factor alpha and
monocyte chemoattractant protein-1, but increased IL-
10 expression [17]. Moreover, MSCs induced a shift in
the macrophage phenotype from inflammatory (M1) to
reparative (M2), uncovering their immunomodulatory
potential [37]. Taken together, these observations under-
score the contribution of paracrine actions of MSCs to
induce a shift from an inflammatory to an anti-
inflammatory microenvironment. It is not unlikely that
the type, number, and expansion methods used to secure
MSCs alter their engraftment capacity.
Rejection
For many years, MSCs have been considered immune pri-
vileged because of the lack of expression of co-stimulatory
molecules and their capacity to decrease renal release and
expression of inflammatory mediators [17,33,37]. These
attributes engendered the hope that MSCs could engraft
in allogeneic nonimmunosuppressed recipients, and stim-
ulated development of off-the-shelf allogeneic MSC prod-
ucts [38], which allow rapid generation of large amounts
of cells from few donors. Nevertheless, in vivo and in vitro
studies have demonstrated that MSCs may occasionally
induce an immune switch transitioning from an immuno-
privileged to an immunogenic phenotype that triggered
cellular cytotoxicity or immune rejection [39]. Moreover,
implantation of murine MSCs engineered to release
erythropoietin in major histocompatibility complex-
mismatched allogeneic mice increased the proportion of
host-derived lymphoid CD8+ and natural killer infiltrating
cells, suggesting that MSCs are not intrinsically immuno-
privileged [40]. Taken together, these observations do not
support the use of allogeneic MSCs as a universal cellular
platform, at least until development of unequivocally
immunoprivileged MSCs. Therefore, at this point, admin-
istration of autologous MSCs seems to be the safest
strategy.
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An important feature of MSCs is their capacity to induce
proliferation of renal glomerular and tubular cells, in-
creasing cellular survival. By secreting proangiogenic
and trophic factors, injected MSCs not only can enhance
proliferation, but also can decrease apoptosis of tubular
cells [32]. We have shown in swine renovascular disease
that a single intrarenal delivery of MSCs in conjunction
with renal revascularization increased proliferation of
renal cells [16], and recently confirmed in vitro that
MSCs blunt apoptosis by decreasing the expression of
caspase-3 [15].
However, whether MSCs remain in the circulation long
enough to exert any long-lasting effect is a matter of de-
bate. Ezquer and colleagues showed that intravenous
MSCs home into the kidney of type 1 diabetic mice, and
some donor MSCs remained in the kidney up to 2 months
later [11]. Similarly, we found that 4 weeks after intrarenal
delivery a significant number of MSCs were retained in
the injected kidney [16,17], whereas by 12 weeks after cell
transfer only a few cells were observed in the kidney, yet
their beneficial effects were sustained [15]. Longitudinal
studies are needed to document the chronology of MSC
retention and beneficial benefits in the kidney. Addition-
ally, development of novel interventions such as precondi-
tioning may enhance survival and potency of MSCs in
renal failure. For instance, MSCs exposed to hypoxic con-
ditions in culture sustain viability and function through
preservation of oxidant status [41], and preconditioning
with kallikrein [26] or melatonin [27] enhances their
therapeutic potential.
An important challenge for clinical translation is the
risk for long-term MSC maldifferentiation. While intrar-
enal injection of rat MSCs initially preserves renal func-
tion in a rat model of glomerulonephritis, a significant
proportion of the glomeruli subsequently contained
large adipocytes with glomerular sclerosis [42]. Further-
more, reports of sarcoma [43] and teratoma [44] arisingFigure 2 Mesenchymal stem cell release microvesicles. Transmission el
image (right) showing release of microvesicles (arrows) from adipose tissuefrom exogenous MSCs illustrate their potential for trans-
formation into tumors, underscoring the requirement
for closely monitoring human MSCs in clinical studies.
Alternatively, complications and maldifferentiation of
live replicating MSCs warrant development of safer tac-
tics and interventions.
Considerable evidence shows that MSCs release
microvesicles which exhibit characteristics of their par-
ental cells, and transfer proteins, lipids, and genetic ma-
terial to target cells. We have recently shown that
endothelial outgrowth cells release microvesicles [45],
which may mediate their intercellular communications.
Similarly, MSCs are avid producers of microvesicles [46]
(Figure 2) that shuttle functional components for their
paracrine action [47]. Delivery of microvesicles instead
of their parent MSCs could avoid concerns about exten-
sive expansion, cryopreservation, complications, and
maldifferentiation of live replicating cells. Indeed, micro-
vesicles derived from preconditioned MSCs promoted
recovery in a rat hind-limb ischemia model [48]. How-
ever, questions regarding their composition and potency
relative to their parent MSCs remain unanswered,
underscoring the need for studies to clarify the potential
of this promising therapeutic modality.
Uremic conditions may also affect the efficacy of MSCs,
limiting their potential use in patients with CKD. Uremia
induced by partial kidney ablation in C57Bl/6 J mice leads
to MSC functional incompetence, characterized by de-
creased expression of VEGF, VEGF receptor-1, and stro-
mal derived factor-1, increased cellular senescence, and
decreased proliferation [49]. Conversely, MSCs isolated
from subcutaneous adipose tissue of healthy controls and
patients with renal disease show similar characteristics
and functionality, underscoring the feasibility of autolo-
gous cell therapy in patients with renal disease [50]. In-
deed, a recent meta-analysis of prospective clinical trials
that used intravascular delivery of MSCs concluded that
these cells have an excellent safety record [51].ectron microscopy image (left) and scanning electron microscopy
-derived mesenchymal stem cells (×26,500).
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Although it is accepted that MSCs from different species
are capable of differentiation into various lineages and ex-
press common MSC markers, species-dependent variability
in their expression has been reported among different spe-
cies [52]. Furthermore, the mechanism of MSC-mediated
immunosuppression varies among different species. For ex-
ample, while immunosuppression by human-derived or
monkey-derived MSCs is mediated by indoleamine 2,3-
dioxygenase, the molecular mechanisms underlying im-
munosuppression in mouse MSCs utilize nitric oxide [53].
Several immune barriers have been also encountered in ex-
perimental xenotransplantation, the transplantation of
MSCs from one species to another, warranting the develop-
ment of genetic alternatives to overcome these obstacles
[54]. Clearly, results from experimental studies need to be
carefully validated before clinical translation.
Tracking
There is also a pressing need for better methods for detec-
tion and monitoring the fate of MSCs. Despite improve-
ment in direct (fluorescent probe) [55] and indirect
(reporter genes) [56] labeling techniques, questions re-
garding interactions of MSCs with tissue, differentiation,
or migration remain unanswered. While fluorescent
probes such as membrane tracers or microspheres need to
be detected with histological techniques in a cell or organ-
elle, reporter genes such as bioluminescence or fluores-
cent proteins can be used to identify different cell
populations using imaging in vivo [57,58]. However, these
detection methods have little tissue penetration, limiting
their use in large animal models or humans [59].
Conceivably, imaging modalities such as single-photon
emission computed tomography or magnetic resonance
imaging may address some of these deficiencies by provid-
ing high-resolution anatomical detail and tracking of cell
viability [60,61]. Several types of agents are currently used
for labeling MSCs for their detection with magnetic reson-
ance imaging. Among them, superparamagnetic iron
oxide particles are the most commonly applied, because of
their capacity to induce changes in T2 relaxivity in vivo
[62]. However, the transfection agents used for superpara-
magnetic iron oxide particle internalization may also affect
cell viability, and dying cells accumulate iron until dis-
solved or eliminated by phagocytosis, impeding their ap-
plication as indices of cell viability. Further methods are
therefore needed to better assess engraftment, survival,
and function of MSCs in human subjects.
Clinical trials using mesenchymal stem cells for
renal repair
Few clinical trials have tested safety and efficacy of
MSCs for renal disease. Reinders and colleagues studiedsafety and feasibility in six kidney allograft recipients
who received two intravenous infusions of expanded au-
tologous bone marrow-derived MSCs (106 cells/kg,
7 days apart) because of rejection and/or increased inter-
stitial fibrosis and tubular atrophy [63]. Although the de-
sign of the study does not allow one to draw conclusions
on efficacy, in two recipients with allograft rejection the
renal biopsies after MSC treatment demonstrated reso-
lution of tubulitis without interstitial fibrosis and tubular
atrophy, whereas maintenance immune suppression
remained unaltered, supporting the potential of MSCs in
preventing allograft rejection. However, three patients
developed an opportunistic infection, raising concerns
regarding systemic immunosuppression after MSC infu-
sions. Similarly, a recent prospective, open-label, ran-
domized study demonstrated that, among patients
undergoing renal transplant, intravenous infusion of
marrow-derived autologous MSCs (1 × 106 to 2 × 106/kg)
at kidney reperfusion and 2 weeks later decreased the in-
cidence of acute rejection and of opportunistic infection,
and improved renal function at 1 year compared with
anti-IL-2 receptor antibody induction therapy [64]. Im-
portantly, delivery of autologous MSCs was not associ-
ated with adverse events, nor did it compromise graft
survival. Likewise, autologous MSC infusion in two re-
cipients of kidneys from living-related donors 7 days
post-transplant restricted memory T-cell expansion and
enlarged the T-regulatory cell population [65]. These ob-
servations suggest safety and clinical feasibility of cell-
based therapy with MSCs in the context of kidney
transplantation.
Several clinical trials are currently underway to
evaluate the therapeutic potential of autologous and
allogeneic MSCs for treatment of renal diseases [66].
For example, NCT01843387 investigates the safety,
tolerability and efficacy of a single intravenous infu-
sion of two doses of MSCs versus placebo in subjects
with diabetic nephropathy and type 2 diabetes.
NCT00659620 will test whether MSCs are effective in
preventing organ rejection and maintaining kidney
function in patients who develop chronic allograft ne-
phropathy. In addition, NCT00659217 evaluates infu-
sion of expanded autologous MSCs into patients with
lupus nephritis. Finally, NCT01840540 is a phase I
study of autologous MSCs in the treatment of athero-
sclerotic renal artery stenosis. While they aim primar-
ily to test the feasibility and practical usefulness of
MSCs in renal diseases, results from these clinical tri-
als may also shed light on the mechanisms respon-
sible for MSC renal protection.
Conclusions and future perspectives
Available experimental evidence confirms that MSCs
contribute to cellular repair and ameliorate renal injury
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studies suggest their capacity to repair the damaged kid-
ney, several barriers need to be circumvented in order to
consider MSCs as a realistic clinical tool to treat CKD.
Among them, systemic immunosuppression and adipo-
genic/malignant transformation raise major concerns.
Additionally, the route of MSC delivery and complexity
of CKD patients (for example, uremia) should be consid-
ered when designing clinical studies. Development of
novel therapies such as microvesicles and precondition-
ing might promote engraftment and MSC communica-
tion with injured parenchymal cells. Further large
controlled clinical trials are needed to assess the efficacy
and safety profile of MSCs in CKD.Note: This article is part of a thematic series on Stem cells in
genitourinary regeneration edited by John Jackson. Other articles
in the series can be found online at http://stemcellres.com/
series/genitourinaryAbbreviations
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